Highest-materiality recent filing
BridgeBio raises $1B in convertible preferred equity from Sixth Street and KKR
Sixth Street invested $800M and HCRx (KKR affiliate) invested $133.9M in Series A convertible preferred stock.
FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026
FDA accepted NDA with Priority Review for BBP-418 to treat LGMD2I/R9; PDUFA target action date November 27, 2026.
NDA submitted for encaleret, a potential first approved therapy for autosomal dominant hypocalcemia type 1 (ADH1).
BridgeBio Pharma establishes $500M at-the-market equity offering program
Up to $500M in common stock may be sold via ATM through Goldman Sachs and Leerink Partners.
BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized
Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.
BridgeBio submits NDA to FDA for BBP-418 for LGMD2I/R9; potential first approved therapy
NDA submission for oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9.
BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials
Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).
BridgeBio reports positive Phase 3 infigratinib results in achondroplasia; NDA/MAA planned H2 2026
PROPEL 3 met primary endpoint: change from baseline in AHV at Week 52 (p<0.0001); mean treatment difference +2.10 cm/year.
BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes
Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.
BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026
Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.
BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint
76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).
Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.
BridgeBio Phase 3 FORTIFY study hits all primary and secondary endpoints for BBP-418 in LGMD2I/R9
Primary endpoint: glycosylated αDG increased 1.8x from baseline at 3 months (p<0.0001); sustained at 12 months.
BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M
Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.
BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments
Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.
BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances
First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.
BridgeBio Pharma appoints Thomas Trimarchi as President and CFO; former CFO departs
Brian Stephenson's employment ended March 17, 2025; receives 9 months base salary and COBRA.
BridgeBio closes $575M 1.75% convertible notes due 2031; refinances Blue Owl secured debt
Issued $575M aggregate principal of 1.75% convertible senior notes due March 1, 2031.
Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.
Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.
FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization
Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).
BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024
Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.
Phase 1/2 ADventure trial of BBP-631 in classic CAH: increased endogenous cortisol in all higher-dose patients (max change 6.6 µg/dL post-ACTH); well tolerated with no treatment-related SAEs.
BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake
BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29
Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.
Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).
BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT
Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.
BridgeBio prices $250M public offering at $29.00/share; funds acoramidis launch and pipeline
8,620,690 shares priced at $29.00; underwriters have 30-day option for 1,293,103 additional shares.
BridgeBio licenses acoramidis to Bayer for EU rights; up to $310M milestones plus royalties
Eidos grants Bayer exclusive license to develop/commercialize acoramidis (AG10) for ATTR amyloidosis in EU and European Patent Organization.
Acoramidis NDA accepted by FDA; PDUFA Nov 29, 2024. Phase 3 met primary endpoint (Win Ratio 1.8, p<0.0001).
BridgeBio secures $500M royalty financing for acoramidis and $450M term loan, repays existing debt
Funding Agreement: $500M from LSI/CPPIB upon FDA approval of acoramidis; 5% royalty on global net sales, cap $950M.
BridgeBio Q3 net loss $177M; acoramidis NDA filing by year-end
Net loss attributable to common stockholders $177M ($1.08 per share) vs $137M ($0.93) YoY.
BridgeBio Pharma raises $250M in PIPE financing led by Qatar Investment Authority
Issues 9,167,723 shares at $27.27/share (Sept 22 close); gross proceeds ~$250M.
Phase 3 ATTRibute-CM of acoramids achieved highly significant primary endpoint, Win Ratio 1.8 (p<0.0001); NDA filing planned by end 2023.
BridgeBio Phase 3 acoramidis hits primary endpoint in ATTR-CM; NDA planned by year-end 2023
Primary endpoint met with Win Ratio 1.8 (p<0.0001); 81% on-treatment survival vs 74% placebo.
BridgeBio Q1 net loss narrows to $140M ($0.92 loss per share); cash $467M after $150M offering
Net loss attributable to common stockholders $140.2M ($0.92 diluted EPS) vs $196.4M ($1.35) in Q1 2022; revenue $1.8M flat.
BridgeBio enters $450M ATM equity offering program; terminates prior $500M facility
ATM allows sale of up to $450M in common stock at Company's discretion; 3% commission to agents.
BridgeBio Pharma prices $150M public offering of common stock at $17.00/share
Offering of 8,823,530 shares (plus underwriters' 30-day option for 1,323,529 shares) at $17.00/share.
Mean change from baseline in annualized height velocity (AHV) at six months: +3.03 cm/yr (p=0.0022) in Cohort 5 (0.25 mg/kg daily).
BridgeBio Q4 net loss $0.92/sh; cash $466M; board adds McCormick; acoramidis data mid-2023
Net loss attributable to common stockholders $137.6M in Q4 ($0.92/sh); full year $481.2M ($3.26/sh).
Q3 operating costs $129.5M, down 26.2% from Q1 2022; net loss $137.3M vs $155.9M prior year.
QED Therapeutics, BridgeBio subsidiary, received termination notice from Helsinn for infigratinib oncology license agreement.
BridgeBio Q2 2022 revenue $73.7M, net loss $9.9M; cash $688.6M; pipeline data positive
Net loss attributable to common stockholders of $9.9M ($0.07 per share) vs $96.3M loss a year ago; revenue $73.7M from NULIBRY and licensing.
The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).
Neil Kumar, Ph.D. stepped down as President
Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer
On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller.
Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.
the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
Max materiality 1.00 · Median 0.75 · Most common event other_material